Immunogenicity of biosimilars
- At: 2008 FIP Congress in Basel (Switzerland)
- Type: Presentation
- By: JISKOOT, Wim (LACDR, Leiden University, Leiden, Netherlands)
- Co-author(s): Schellekens, Huub (Utrecht University, Utrecht, Netherlands)
Since the introduction of hybridoma and recombinant DNA technologies more than 30 years ago, more than 150 proteins have entered the clinic as hormones, growth factors, immune-modulating agents and monoclonal antibodies. Moreover, hundreds of biopharmaceuticals are in the pipeline. These products are life-saving and/or increase the quality of.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.